GNAS and cancer: Although POH has been reported to inhibit various oncogenic pathway, including RAS (27–29), NF-κB (30), and AP-1 signaling (31), and upregulate cyclin-dependent kinase inhibitors including p15 (32), p21 (32, 33), and p27 (33), to our knowledge, the present study is the first report showing the direct target of POH in cancer cells.